pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk A/S clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Novo Nordisk A/S projects
4 ClinicalTrials.gov programs sponsored by Novo Nordisk A/S.
Novo Nordisk A/S has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Faster Aspart
Novo Nordisk A/S
Diabetes Mellitus, Type 1
1 trial -
NNC 0172-0000-2021
Novo Nordisk A/S
Congenital Bleeding Disorder
1 trial -
NNC0480-0389
Novo Nordisk A/S
Healthy Volunteers Type 2 Diabetes
1 trial -
To evaluate the pharmacokinetics and safety of nolasiban
Novo Nordisk A/S
not applicable (submitted trial is a pharmacokinetic study in healthy subjects)
1 trial
Frequently asked questions
How many clinical projects does Novo Nordisk A/S have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.